TSE:4528Pharmaceuticals
Does Ono’s Expanding Oncology Pipeline and Qinlock Filing Reshape The Bull Case For Ono (TSE:4528)?
In recent trading, Ono Pharmaceutical reported progress across its oncology and specialty medicine portfolio, including regulatory advances for Opdivo, expanded development of Velexbru, positive mid-stage data for ONO-4578 and ONO-2808, and a regulatory filing for Qinlock in Japan.
These developments, alongside the launch of newer products like Romvimza and a broader rare disease and cancer portfolio, highlight Ono’s effort to diversify revenue sources beyond a single blockbuster...